Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate
NCT05542147
·
clinicaltrials.gov ↗
NA
Phase
COMPLETED
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Type 2 Diabetes
Cardiovascular Diseases
Pharmacogenomic Drug Interaction
Interventions
DRUG:
Fenofibrate 145 mg
DRUG:
Placebo
Sponsor
Mario Luca Morieri